Solid Tumors

Undefeated

I’m sure every cancer survivor feels this way, but my diagnosis, in 1997, of stage III germ cell testicular cancer couldn’t have come at a worse time in my life. I was nearing the end of a 60-city tour...

Symptom Management

Physician-Patient Partnership Is Key to Recognizing and Managing Side Effects of Immune Checkpoint Inhibitors

“Immunotherapy has a completely different side-effect profile than chemotherapy, and that has caught physicians off guard,” noted Drew Pardoll, MD, PhD, in an article...

Lymphoma

BTK Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma

A phase II study (ACE-LY-004) reported in The Lancet by Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, and colleagues showed durable responses...


Advertisement
Lung Cancer

FDA Approves Osimertinib for First-Line Treatment of Metastatic NSCLC With Most Common EGFR Mutations

On April 18, the U.S. Food and Drug Administration approved osimertinib for the first-line treatment of patients with metastatic non–small cell lung cancer whose tumors have epidermal growth factor receptor....

Colorectal Cancer

Following Nutrition and Exercise Guidelines May Prolong Survival in Stage III Colon Cancer

A diet high in whole grains, fruits, and vegetables—along with exercise and maintaining a healthy body weight—can improve the 5-year survival rate for patients...


More Top Stories

Survivorship

Christopher J. Recklitis, PhD, MPH, on Mental Health in Cancer Survivors

Yale Cancer Center Launches Immuno-Oncology Center

Yale Cancer Center has launched the Yale Center for Immuno-Oncology. The new center will build on Yale Cancer Center’s international leadership in immunobiology, cancer immunology, and development of novel cancer immunotherapies. It is a partnership between Yale Cancer Center and the Department of...

Advertisement

Reciprocal Risks of Lymphoid Neoplasms and Cutaneous Melanoma

In a study reported in the Journal of the National Cancer Institute, Herr et al found that patients with specific types of primary lymphoid neoplasms were at increased risk of second primary cutaneous melanoma, with the reciprocal association also being observed. Occurrence of second primary...

Kidney Cancer

Sumanta K. Pal, MD, on RCC: Results From Two Clinical Trials

Lymphoma

FDA Expands Approval of Brentuximab Vedotin in Classical Hodgkin Lymphoma

ON MARCH 20, the U.S. Food and Drug Administration (FDA) approved brentuximab vedotin (Adcetris), an antibody-drug conjugate, to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy. Brentuximab vedotin combines an antibody and...

Head and Neck Cancer

Delays in Radiation Therapy After Surgery for Head and Neck Cancer Linked to Decreased Survival

DELAYS IN RADIATION THERAPY after surgery for head and neck cancer were associated with decreased survival in a large population of U.S. patients, according to data presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium and reported online recently in JAMA Otolaryngology Head & ...

FDA Approves Osimertinib for First-Line Treatment of Metastatic NSCLC With Most Common EGFR Mutations

On April 18, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as...

Issues in Oncology

Abe Lopman, MBA, on The Business of Cancer

Head and Neck Cancer

Intratumor Heterogeneity of Head and Neck Cancers May Have Therapeutic Implications

A RETROSPECTIVE STUDY of The Cancer Genome Atlas may have therapy-specific implications for patients with head and neck squamous cell carcinoma, according to data presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium.1 This first analysis of the relationship between intratumor...

Advertisement

Following Nutrition and Exercise Guidelines May Prolong Survival in Stage III Colon Cancer

A diet high in whole grains, fruits, and vegetables—along with exercise and maintaining a healthy body weight—can improve the 5-year survival rate for patients with stage III colorectal cancer, according to a new report published by Van Blarigan et al in JAMA Oncology. The findings...